# Tirzepatide: The Dual GIP/GLP-1 Molecule — Cardiometabolic Research Digest

> Tirzepatide is the first dual incretin agonist, engaging both GIP and GLP-1 receptors. The cardiometabolic trial record — SURPASS, SURMOUNT, blood pressure, lipids, and weight — read straight and cited.

The cardiometabolic evidence from SURPASS, SURMOUNT, and the extended programme, read straight from the citations. C225H348N48O68. CAS 2023788-19-2. FDA-approved 2022.

## The short version

Tirzepatide is a synthetic peptide drug — a long chain of 39 amino acids — that the FDA approved in May 2022 for type 2 diabetes and then in November 2023 for weight loss. It works differently from earlier diabetes medications: most drugs of its class target one gut-hormone receptor, but tirzepatide targets two at once — both the GIP receptor and the GLP-1 receptor ("GIP" and "GLP-1" are hormones your gut releases after eating that tell your pancreas to release insulin). Hitting both receptors produces larger effects on blood sugar, body weight, blood pressure, and cholesterol than hitting just one. In the biggest clinical trial, people on the highest tested dose lost about 21% of their body weight over 72 weeks. Blood pressure dropped by several mmHg. The lipid panel improved across the board. What people report — the benefits and the downsides — is on [the effects page](/effects). This site is a plain-English digest of the published research, with every number traced to a trial.

## What Tirzepatide has demonstrated in the trial record

Tirzepatide has produced the largest glycaemic and weight reductions measured in a pivotal-phase incretin trial programme. In SURPASS-2 — a 40-week head-to-head trial in 1,879 adults with type 2 diabetes — once-weekly tirzepatide at 5, 10, and 15 mg reduced HbA1c (glycated haemoglobin, a measure of blood glucose control over roughly three months) by 2.01, 2.24, and 2.30 percentage points, compared with 1.86 percentage points for a selective GLP-1 receptor agonist comparator; tirzepatide was superior at all three doses [3]. Body weight fell 1.9, 3.6, and 5.5 kg more than with the comparator [3].

In SURMOUNT-1 — a 72-week trial in 2,539 adults with obesity and without diabetes — mean weight change at week 72 was -15.0%, -19.5%, and -20.9% at 5, 10, and 15 mg, versus -3.1% with placebo [4]. Head-to-head against a selective GLP-1 receptor agonist in SURMOUNT-5, tirzepatide produced a least-squares mean weight change of -20.2% versus -13.7% at 72 weeks [5].

The cardiometabolic-outcomes lens extends beyond body weight. A meta-analysis of seven randomised controlled trials found dose-dependent systolic blood-pressure reductions of -4.20 mmHg (5 mg), -5.34 mmHg (10 mg), and -5.77 mmHg (15 mg), alongside reductions in LDL-cholesterol and triglycerides and an increase in HDL-cholesterol [10]. A pooled SURPASS-programme analysis reported clinically meaningful systolic blood-pressure reductions across the full programme [8]. A SURPASS-CVOT post-hoc analysis found a 16% lower incidence of a six-component cardiovascular-and-kidney composite endpoint versus a GLP-1 receptor agonist comparator in adults with type 2 diabetes and established cardiovascular disease (HR 0.84) [13].

The chemistry behind these readouts is distinctive: tirzepatide is a 39-amino-acid peptide built on the native GIP backbone, with a C20 fatty-diacid (eicosanedioic acid) arm attached via a glutamic-acid linker and two AEEA units to a lysine side chain. That fatty-diacid arm binds albumin, conferring an elimination half-life of approximately five days and enabling once-weekly subcutaneous dosing [1]. In vitro assays characterised it as an imbalanced dual agonist — engaging the GIP receptor more fully than the GLP-1 receptor and showing biased GLP-1 receptor signalling that favours cAMP generation over beta-arrestin recruitment [2]. The molecular formula is C225H348N48O68; molecular weight 4,813.53 Da; CAS 2023788-19-2; ATC A10BX16.

This site is an independent editorial digest of the published [Tirzepatide research](/research). Every quantitative claim is cited. No clinical advice, no vendor links, nothing sold here.

## Tirzepatide mechanism of action

Incretin hormones — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) — are released from the gut wall after a meal. They travel to the pancreas, where they amplify glucose-dependent insulin secretion. Historically, drug developers focused on GLP-1 alone; tirzepatide added the GIP arm.

Engaging both receptors with a single molecule enhances glucose-dependent insulin secretion and suppresses glucagon (a hormone that raises blood glucose), while simultaneously slowing gastric emptying (the speed at which the stomach passes food onward) and reducing appetite signalling in the central nervous system. The combination produces glycaemic and weight reductions larger than selective GLP-1 receptor agonism alone across the SURPASS and SURMOUNT programmes [1].

The imbalanced-biased-agonism profile — GIP receptor preferred over GLP-1 receptor; cAMP pathway preferred over beta-arrestin at the GLP-1 receptor — is proposed to reduce desensitisation and enhance the insulin-secretory response compared with balanced agonists [2]. For the full mechanism discussion, see [Tirzepatide research](/research).

## Tirzepatide peptide: chemical identity at a glance

Tirzepatide peptide is a linear synthetic peptide, not a small molecule. Key identifiers:

- **Molecular formula**: C225H348N48O68
- **Molecular weight**: 4,813.53 Da
- **CAS number**: 2023788-19-2
- **ATC code**: A10BX16
- **Structure**: 39-amino-acid chain based on the native GIP backbone; C20-eicosanedioic-acid diacid arm attached via glutamic acid linker + two (2-(2-aminoethoxy)ethoxy)acetic acid (AEEA) units to a lysine side chain
- **Half-life**: approximately 5 days (supports once-weekly dosing)
- **Route**: subcutaneous injection only (all clinical-trial and approved formulations)

The fatty-diacid arm is the engineering decision that separates it from early-generation GLP-1 receptor agonists: it confers high albumin affinity, extending circulation time to five days and making once-weekly dosing viable [1, 2].

## Tirzepatide results across the programme at a glance

The SURPASS and SURMOUNT programmes produced consistent, dose-ordered cardiometabolic readouts:

- **HbA1c** (type 2 diabetes): -2.01 to -2.30 percentage-point reductions across doses at 40 weeks (SURPASS-2) versus -1.86 with a selective GLP-1 comparator [3]
- **Body weight** (obesity, no diabetes): -15.0%, -19.5%, -20.9% at 5/10/15 mg at 72 weeks (SURMOUNT-1) versus -3.1% placebo [4]
- **Head-to-head weight** (SURMOUNT-5, 72 weeks): -20.2% versus -13.7% with a selective GLP-1 comparator [5]
- **Systolic blood pressure**: -4.20, -5.34, -5.77 mmHg at 5/10/15 mg (meta-analysis, 7 RCTs) [10]
- **LDL-cholesterol and triglycerides**: reduced; HDL-cholesterol: increased across doses [10]
- **Cardiorenal composite** (SURPASS-CVOT, established cardiovascular disease): HR 0.84 versus a GLP-1 comparator [13]

For [tirzepatide weight loss](/weight-loss) evidence and for the full [Tirzepatide effects](/effects) picture — benefits, adverse effects, and safety cautions — follow the relevant pages.

---

The chemistry and trial record of a dual-receptor agonist, read independently — no clinic, no product, no prescription.